Status:
COMPLETED
Dose-Response of Salmeterol in Children
Lead Sponsor:
University of Florida
Collaborating Sponsors:
Teva Branded Pharmaceutical Products R&D, Inc.
Conditions:
Asthma
Eligibility:
All Genders
4-11 years
Phase:
PHASE4
Brief Summary
To examine whether a breathing test (methacholine challenge using impulse oscillometry) can be used to tell the difference between two different doses of an inhaled drug, salmeterol, delivered by Adva...
Detailed Description
During the study the subject will have to attend 4 study visits: 2 screening visits and 2 treatment visits. Before each study visit, the subject has to stop using certain asthma medications. At Scre...
Eligibility Criteria
Inclusion
- parent/legal guardian and subject must be able to speak and understand English and patient must be willing and able to give assent to take part in the study
- diagnosed with asthma for at least 6 months
- able to demonstrate inhalation technique with study device
- if taking inhaled corticosteroids, dose must be stable for 2 weeks
- no significant concomitant medical conditions or abnormal physical findings on screening except for those consistent with asthma and allergic rhinitis
- airway responsiveness to methacholine with a baseline provocational dose causing an increase of at least 40% in R5 (PC40R5) at no more than 8 mg/mL
Exclusion
- female who has started menstruating
- past or present history of any allergic reaction to any of the medications or formulations administered in this study
- prior treatment with systemic corticosteroids in last 30 days or more than 4 courses in previous 12 months
- use of short-acting beta-agonist more than two times per week in the previous month
- use of long-acting beta-agonist in the 3 weeks before the first methacholine challenge or during the study
- change in dosage of inhaled corticosteroids in previous 30 days, nasal steroids in previous 15 days and montelukast in last 7 days
- history of life-threatening asthma, including loss of consciousness, intubation and/or admission to ICU
- hospitalization for acute asthma within past year
- inability to withhold the following medications before methacholine challenges:
- short-acting beta-agonists at least 6 hours
- regular long-acting beta-agonists at least 3 weeks
- inhaled corticosteroid at least 2 hours
- montelukast at least 24 hours
- aspirin and non-steroid anti-inflammatory drugs at least 48 hours
- caffeine at least 4 hours
Key Trial Info
Start Date :
August 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2014
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01907334
Start Date
August 1 2013
End Date
July 1 2014
Last Update
October 7 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Florida Asthma Research Lab
Gainesville, Florida, United States, 32610-0486